Author/Authors :
Wojnicz، نويسنده , , Romuald and Wilczek، نويسنده , , Krzysztof and Nowalany-Kozielska، نويسنده , , Ewa and Szygu?a-Jurkiewicz، نويسنده , , Bo?ena and Nowak، نويسنده , , Jolanta and Polo?ski، نويسنده , , Lech and Dyrbu?، نويسنده , , Krzysztof and Badzi?ski، نويسنده , , Arkadiusz and Mercik، نويسنده , , Gabriela and Zembala، نويسنده , , Marian and Wodniecki، نويسنده , , Jan and Rozek، نويسنده ,
Abstract :
This study evaluated the safety, tolerability, and efficacy of statin therapy in patients with heart failure secondary to inflammatory dilated cardiomyopathy and moderately elevated low-density lipoprotein cholesterol levels. Seventy-four patients were randomized to receive atorvastatin 40 mg/day or conventional treatment for heart failure. After 6 months of therapy, the predefined primary efficacy end point (an increase of >5% in the absolute left ventricular ejection fraction and ≥2 selected criteria by echocardiography and a decrease in New York Heart Association functional class) was significant in the statin-treated patients (p = 0.004). Among secondary efficacy parameters, the quality-of-life index showed a trend suggesting the benefit of statin therapy (p = 0.055). In conclusion, the results of this study demonstrate that treatment with atorvastatin in addition to standard therapy for heart failure may significantly improve clinical outcomes in this cohort of patients.
